Abstract | OBJECTIVE: METHOD: Anti-N was assessed in both serum and cerebrospinal fluid (CSF) samples from 38 patients with CNS-SLE, 29 with SLE without CNS involvement (non-CNS-SLE), 36 with other rheumatic diseases and 59 with non- rheumatic diseases with the CNS manifestations using a cell-ELISA method with 1% paraformaldehyde-fixed SK-N-MC neuroblastoma cells as substrate. Serum samples from 37 healthy donors were also included in this study. Patients with CNS-SLE who were anti-N positive in CSF were studied serially for CSF anti-N levels at times of treatment-associated improvement in CNS symptoms. RESULTS: Serum anti-N levels were significantly increased in patients with SLE compared with other groups, with a sensitivity of 61.2% (41/67) and a specificity of 91.8% (p<0.001). CSF anti-N levels were significantly increased in patients with CNS-SLE, with a sensitivity of 47.4% (18/38) and a specificity of 89.7%, whereas only 10.3% (3/29) of patients with non-CNS-SLE had increased anti-N in CSF (p<0.001). CSF anti-N levels decreased significantly after effective treatment of CNS-SLE (p<0.05). CONCLUSION: Serum anti-N is relatively specific to SLE. CSF anti-N is a sensitive and relatively specific antibody in diagnosing CNS-SLE and correlates with CNS-SLE activity.
|
Authors | Xuan Zhang, Huijun Shu, Fengchun Zhang, Xinping Tian, Yi Dong |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 66
Issue 4
Pg. 530-2
(Apr 2007)
ISSN: 0003-4967 [Print] England |
PMID | 16905576
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Autoantibodies
- Biomarkers
|
Topics |
- Adolescent
- Adult
- Autoantibodies
(analysis, blood, cerebrospinal fluid)
- Biomarkers
(blood, cerebrospinal fluid)
- Enzyme-Linked Immunosorbent Assay
(methods)
- Female
- Humans
- Lupus Erythematosus, Systemic
(immunology)
- Lupus Vasculitis, Central Nervous System
(diagnosis)
- Male
- Middle Aged
- Neurons
(immunology)
- Sensitivity and Specificity
|